5-azacytidine reverses drug resistance in bladder cancer cells.
Anticancer Res
; 31(11): 3757-66, 2011 Nov.
Article
em En
| MEDLINE
| ID: mdl-22110197
ABSTRACT
BACKGROUND:
Patients with metastatic and muscle-invasive bladder cancer are commonly treated with cisplatin. A significant proportion of patients develop disease progression after an initial response to chemotherapy. Presently there is no standard of care for such patients. We examined whether pretreatment with an epigenetic agent would result in reversal of drug resistance. MATERIALS ANDMETHODS:
Methylation of proapoptotic and cell cycle genes in bladder cancer cells was examined. Cisplatin- and docetaxel-resistant cells were generated. The effect of target of methylation-induced silencing (TMS1) expression and pretreatment of wild-type and drug-resistant cells with 5-azacytidine on chemosensitivity was determined.RESULTS:
Unidirectional crossresistance of cisplatin-resistant UMUC3 cells to docetaxel was observed. Recombinant expression of TMS1 or pre-treatment of wild-type and drug-resistant cells with 5-azacytidine resulted in enhanced sensitivity to cisplatin and docetaxel.CONCLUSION:
Our results indicate that epigenetic therapy may restore sensitivity to chemotherapeutic agents in bladder cancer cells.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Azacitidina
/
Neoplasias da Bexiga Urinária
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Resistencia a Medicamentos Antineoplásicos
/
Proteínas do Citoesqueleto
/
Antimetabólitos Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2011
Tipo de documento:
Article